focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Nice to see more articles appearing now
UK-based biotech submits patent for transformational treatment of non-alcoholic fatty liver disease (NAFLD).
Genflow has announced that it has filed a new patent application with the US Patent and Trademark Office that relates to variants of Sirtuin-6, and the gene variant’s therapeutic uses for the treatment of two disorders involving the liver: non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), an advanced form of NAFLD.
Genflow holds the exclusive licence for this application through Genflow Biosciences, the company’s Belgian subsidiary.
Longevity.Technology: Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of individuals who do not consume excessive amounts of alcohol. A common disorder, it is estimated to affect up to 25% of the global population, and it is often associated with obesity, insulin resistance and type 2 diabetes. Although the exact causes of NAFLD are not fully understood, it is thought that the accumulation of fat in the liver may be due to a combination of factors, including aging, diet and genetics.
NAFLD can progress to more severe liver conditions, such as non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis – which can lead to liver failure and death. Research into NAFLD is key because in understanding the causes and mechanisms of the disease, science can develop effective treatments and preventions. As obesity rates in developed nations continue to climb, so the number of people with NASH, is expected to rise dramatically. In the past decade, large drug-makers including Allergan, Gilead and Novartis have spent billions of dollars acquiring or licensing medicines designed to treat NASH.
Sirtuins are a family of proteins that play important roles in regulating gene expression, metabolism, and stress resistance in the body. Involved in many cellular processes, including DNA repair, inflammation and cell survival, sirtuins are activated by the presence of certain molecules, such as NAD+ and sirtuin-activating compounds. They are found in all organisms, from bacteria to humans, and are thought to play a role in the health and lifespan of organisms; indeed research suggests that sirtuins may be involved in the aging process and may have potential as therapeutic targets for age-related diseases.
Lile, nice post.
Do we have any idea how long the patent process takes. 14 months?
Thought we might have been nearer to 4p than 3p after that RNS. Rerate well and truly on the cards here
Should be flying, said it days ago someone is getting order filled. Can’t be any other reason?
This….
In the past decade, large drugmakers including Allergan, Gilead and Novartis, have spent billions of dollars acquiring or licensing medicines designed to treat NASH.
Big pharma must be sniffing around GENF now for sure. World leader in the field
GLA
I’m sure you can track the patent online. I was following something on an American site that updated again on the 12th December. I’m buying more today! This is so undervalued
Also we have a massive cash runway as stated by the board not long ago. Fully funded for the next 2 years.
Brilliant RNS! Fantastic stuff yet again by the Board. This company is a world leader and a bargain. Strong buy and hold
I was half expecting a placing RNS this morning tbh
For some reason I’m not sure it’s posting correctly
**********************Ih64nav3TSzI1fpN
Welcome aboard, think it’s being held for orders here
Great watch this
Would be brilliant to see something in the next few weeks. Seems very quiet today. Hopefully something is brewing
GLA
Far from a tag team.
Pitty it has fallen back this week. Need a company update or something there hasn’t been one in months.
05-Dec-22 15:06:51 3.45 1,000,000 Unknown* 34.50k
Going off the time of that trade yesterday I’m sure it’s a buy. Would not be surprised to see more big late trades showing tomorrow.
400k late buy I think at 3.60p.
Still well under the IPO price aswell. A gain of over 220% from these levels. Not to mention GENF being far ahead of all peers in this field! An absolute steel and a fantastic opportunity for all to get in and enjoy the journey of this revolutionary company
GLA
Something I think. That or a serious update. GL
Shot upto 3.90p to buy. Someone loading